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Background: Dysphagia is common following Multiple Sclerosis (MS) and is associated with signiﬁcant
morbidity and mortality. The current rehabilitation program to swallowing therapy is Traditional
Dysphagia Therapy (TDT), but there is a dearth of evidence about its effectiveness in MS patients.
Objectives: This study was aimed to determine the effects of the TDT on the swallowing function in MS
patients with dysphagia.
Methods: A pilot double blind randomized clinical trial was carried out on 20 patients with MS. Patients
were randomly divided into experimental group (TDT) comprising sensorimotor exercises and swal-
lowing maneuvers, and Usual Care (UC) comprising diet prescription and postural changes. Patients in
both groups received treatments for 6 weeks, 18 treatment sessions, 3 times per week, every other day.
The Mann Assessment of Swallowing Ability (MASA) was the main outcome measure. The swallowing
ability was assessed before treatment (T0), after the end of 9th session (T1), after the end of 18th session
(T2), and after 6 weeks follow-up (T3). PenetrationeAspiration Scale (PAS) and Pharyngeal Residue Rating
Scale (PRRS) as secondary outcome measures were applied at T0 and T2.
Results: Both groups had improved regarding MASA, PAS and PRRS scores over the time (P< 0.001). The
improvements achieved in all outcomes were signiﬁcantly greater in the TDT group than those of the UC
group. The Main effect of the TimeGroup interaction was signiﬁcant for MASA score (P< 0.001). The
large effect sizes were found for MASA score in both the TDT (d¼ 3.91) and the UC (d¼ 1.11) groups.
Conclusions: This pilot randomized controlled trial showed that the TDT signiﬁcantly improved the
swallowing function of the MS patients with dysphagia.
© 2018 Elsevier Ltd. All rights reserved.1. Introduction
Multiple Sclerosis (MS) is one of the most common neurological
diseases globally that usually affects young adults (Compston andapy, School of Rehabilitation,
arameshlu), lghelichi@gmail.
Azimi), nakhostin@tums.ac.ir
abadi).Coles, 2008; Etemadifar et al., 2014). It can cause clinical and
neurological symptoms such as dysphagia or swallowing disorders
(Milo and Kahana, 2010). Dysphagia is a prevalent symptom in MS
(Hartelius and Svensson, 1994; Merson and Rolnick, 1998; Thomas
and Wiles, 1999; Calcagno et al., 2002) and more than one-third of
the MS patients are affected (Guan et al., 2015).
Dysphagia is a dangerous condition inMS patients because of its
potential complications such as dehydration, malnutrition, and
aspiration pneumonia. Dysphagia and its complications reduce the
quality of life and can lead to morbidity and mortality in the ﬁnal
stages of MS disease (Poorjavad et al., 2010; Guan et al., 2015).
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appropriate therapeutic techniques should be provided, based on a
detailed clinical assessment in MS patients (Giusti and Giambuzzi,
2008).
The goal of dysphagia therapy is to achieve a normal diet, as far
as possible, in the safest and most efﬁcient way (Logemann, 1998).
Treatment of MS related dysphagia includes Traditional Dysphagia
Therapy (TDT) (Prosiegel et al., 2004; Logemann, 2006a,b; Restivo
et al., 2006; Giusti and Giambuzzi, 2008), pharyngeal electrical
stimulation (Restivo et al., 2013), neuromuscular electrical stimu-
lation (Boggardt et al., 2009), and vagal nerve stimulation (Marrosu
et al., 2007).
The current standard swallowing therapy is TDT that includes
behavioral and rehabilitative techniques (Carnaby-Mann et al.,
2006, 2007). The rehabilitative techniques are applied to improve
physiology of the swallowing function and involve sensorimotor
exercises and swallowing maneuvers (Logemann, 1998; Restivo
et al., 2006).
The TDT has been stated as a potential beneﬁcial treatment in
MS patients with dysphagia (Prosiegel et al., 2004; Logemann,
2006a,b; Restivo et al., 2006; Giusti and Giambuzzi, 2008). While
theMS patients with dysphagia undergoing TDTmay improve their
swallowing function, there is no sufﬁcient data on the effect of TDT
on swallowing function in MS population.
The literature on the effects of TDTon swallowing dysfunction in
MS patients is scarce. Thus, the aim of this pilot randomized
controlled trial was to investigate the effects of TDT on the swal-
lowing function in patients with MS.
2. Methods
2.1. Study design
This was a pilot randomized, double-blind, clinical trial to
evaluate the effects of the TDT in MS patients with swallowing
dysfunction. The study protocol was approved by the Research
Council, School of Rehabilitation and the Ethical committee of
Tehran University of Medical Sciences (TUMS). The trial was
registered with the Iranian Registry of Clinical Trials
(IRCT2016022426721N2).
2.2. Patients
The patients were recruited from the MS Clinic of the Sina
University Hospital and MS Research Center of the TUMS in Tehran,
Iran, between February 2015 and November 2016. The inclusion
criteria were: 1) established diagnosis of MS according to the
McDonald's criteria (McDonalds et al., 2001), 2) age between 20
and 60 years, 3) having dysphagia based on DYMUS questionnaire
(Bergamaschi et al., 2009), 4) lack of an acute relapse in the past
two months, 5) no other conditions such as stroke. The exclusion
criteria were: 1) having severe reﬂux, 2) having dysphagia due to
the drug toxicity, 3) being pregnant. All patients signed a consent
form before taking part in the study.
2.3. Randomization
The opaque sealed envelopes were applied for randomization
using a computer-generated randomized list of numbers. Before
data collection, the patients were randomly assigned to one of two
groups of TDT (n¼ 10) or UC (n¼ 10) by secretary of the Dysphagia
Clinic who had no other role in the study. Both patients and
assessor were blinded to treatment allocation. Patients were told
that they will recive one of established treatment protocols. Addi-
tionally, the treatment sessions of the groups were planned in sucha way that the patients of both groups were not aware of the
treatment protocol of each other's. The dysphagia therapist who
was the principal researcher was blinded to the outcomes of as-
sessments, as well.
2.4. Interventions
All patients in both groups received 18 sessions of treatment,
three times a week (every other day). The sessions of treatment
were provided at the Dysphagia Clinic. However, treatment was
provided at home for the patients with motor limitation and
transportation difﬁculties. Before treatment, the patients were
requested not to participate in any other dysphagia treatment
program. During follow up, patients were phone called by the
Speech and Language Pathologist (SLP) once a week to remind
them to perform the exercises according to the instructions given
by the therapist.
2.5. Traditional dysphagia therapy
The TDT strategies are generally designed to change the physi-
ology of swallowing by improving range of motion of the oral and
pharyngeal structures, improving sensory input, and coordinating
the oropharyngeal movements during swallowing (Logemann,
1998, 2006; Carnaby-Mann et al., 2006; Restivo et al., 2006). TDT
includes oral motor control and range of motion exercises, swal-
lowing maneuvers, and strategies to heighten sensory input
(Logemann, 1998; Carnaby-Mann et al., 2006; Restivo et al., 2006).
The details of the TDT strategies are provided in Table 1.
2.6. Usual care
The UC consisted of supervision for feeding and precautions for
safe swallowing. The UC strategies lead to control the food ﬂow and
eliminate the clinical symptoms such as aspiration. However, these
strategies do not change the physiology of the swallowing. The UC
program includes 1) postural changes (chin up, chin down, head
tilt, and head rotation), 2) modifying volume and speed of food
presentation, 3) changing food consistency and viscosity, and 4)
improving sensory oral awareness (presenting a cold bolus and/or a
sour bolus, downward pressure of the spoon against the tongue
(Carnaby-Mann et al., 2006, 2007).
3. Outcome measures
3.1. Primary outcome measure
In this study, the Mann Assessment of Swallowing Ability
(MASA) (Carnaby-Mann, 2002) was used as the main outcome
measure. It was measured before treatment (T0), after the end of
9th session (T1), after the end of 18th session (T2), and 6weeks after
the end of treatment (T3).
The MASA is a comprehensive clinical tool for examination of
neurogenic oropharyngeal dysphagia (Carnaby-Mann, 2002;
Ghelichi et al., 2016). The MASA includes 24 items with the
maximum possible score of 200 for assessing dysphagia
[nil 178e200; mild 168e177; moderate 139e167; and se-
vere 138) and aspiration [nil 170e200; mild 149e169; mod-
erate 148; and severe 140). The MASA is valid and reliable with
a sensitivity of 73% and a speciﬁcity of 89% (Carnaby-Mann, 2002).
In this study, thirty MS patients were recruited in advance to
investigate the interrater and intrarater reliability of the MASA. The
reliability analyses demonstrated good interrater (k¼ 0.76,
SE¼ 0.082, p< 0.001) and intrarater (k ¼ 0.71, SE¼ 0.09, p< 0.001)
reliability.
Table 1
Traditional dysphagia therapy (TDT).
Type of traditional treatment Examples/Description
Exercise programs Oral motor control Exercises
Range of motion tongue Exercises
Resistance Exercises
Bolus control Exercises
Bolus propulsion Exercises
Laryngeal elevation
Pharyngeal swallowing maneuvers Mendelsohn maneuver
Supraglottic swallow
Super supraglottic swallow
Effortful swallow
Masako maneuver
Compensatory swallowing strategies Viscosity changes to food and liquids
Positional changes
Clear throat or cough after each bite/sip
No straws
Place food on right or left side of mouth
Alternate bite/sip
Sensory stimuli Changing the taste, volume, temperature, or carbonation of the bolus
Thermal tactile stimulation
Additional pressure on the tongue with a spoon
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PenetrationeAspiration Scale (PAS) (Rosenbek et al., 1996) and
Pharyngeal Residue Rating Scale (PRRS) were used to quantify the
functional recovery of the swallowing based on the Fiberoptic
Endoscopic Evaluation of Swallowing (FEES). The FEES was per-
formed following the standard protocol (Langmore, 2001). No
topical anesthetic or vasoconstrictor was performed to the patients’
nasal mucosa during FEES. The FEES was applied before treatment
(T0) and after the end of 18th session (T1).
The PAS is a standard scale to assess the laryngeal penetration
and aspiration. Laryngeal penetration is deﬁned as entry of material
into the larynx, but not below the true vocal folds, and the aspi-
ration refers to the entry of material into the airway below the true
vocal folds. The PAS is an eight-point scale based on the depth of
material invasion into the airway and the patient's reaction to these
events. Higher score indicate higher aspiration severity (Rosenbek
et al., 1996).
We applied the PRRS based on commonly used descriptors of
residue severity. It is a ﬁve-point ordinal rating scale to assess the
residue severity (Kelly et al., 2006) (Table 2).3.3. Statistical analysis
Data were analyzed using the Statistical Package for the Social
Sciences (SPSS) version 17. Kolmogorov-Smirnov test was used for
normality analysis of the data. Repeated measure ANOVAwas used
to analyze the main effects of Time, Group and Time*Group inter-
action on the MASA score. Bonferroni test was used for paired
multiple comparisons. Independent t-test and Mann-Whitney test
were used to analyze the between groups comparison of the PAS
and PRRS scores. Paired t-test and Wilcoxon signed-rank test were
applied to within group comparison of the PAS and PRRS scores.Table 2
Pharyngeal residue severity scale (PRRS).
None No pharyngeal coating or residue
Coating Coating of the pharyngeal mucosa; no pooling
Mild Mild pooling/residue
Moderate Moderate pooling/residue
Severe Severe pooling/residueFurthermore, the effect sizes (Cohen's d) of the changed scores
were calculated to determine the treatment effects. P-values .05
were considered as statistically signiﬁcant.
4. Results
The ﬂow chart of participants is shown in Fig. 1. From the initial
130 patients referred by a neurologist, a total of 20 patients [Mean
(SD) age, 43.7 (11.82) years; mean disease duration, 6.6 (2.92) years]
were included in this study and randomly allocated into 2 groups:
experimental, TDT group (n¼ 10) and control, UC group (n¼ 10).
All the patients completed the study protocol. The mean EDSS was
3.4 (SD¼ 2.3). Eleven (55%) patients had Relapse-Remitting (RR),
three patients (15%) had Primary Progressive (PP) MS, and six pa-
tients (30%) had Secondary Progressive (SP) MS. The baseline
characteristics of patients in both groups did not differ signiﬁcantly
(Table 3). There were no signiﬁcant differences in all outcome
measures at baseline between the 2 groups (p> 0.05) (Table 4).
4.1. Primary outcome measure
There was a signiﬁcant effect of Time (p< 0.001) onMASA score.
Bonferroni test revealed that the MASA score had improved
signiﬁcantly across the time in the TDT group (p< 0.001). The im-
provements of MASA scorewasmaintained 6weeks after the end of
the treatment (p¼ 0.1) in the TDT group. There was a signiﬁcant
improvement of the MASA score at the end of 9th session
(p¼ 0.006) in the UC group, however The MASA score was signif-
icantly worsened after 6 weeks follow-up (p¼ 0.04). The main ef-
fect of Group for MASA score was signiﬁcant (p< 0.001). The
TimeGroup interaction was signiﬁcant for the MASA score; F
(1.15, 21.93)¼ 43.69, p 0.001 (Fig. 2). The large effect sizes were
found for MASA score in both the TDT group (d¼ 3.91) and the UC
group (d¼ 1.11).
The frequency of the dysphagia severity in terms of the MASA
test in both groups is demonstrated in Table 5. There was only one
patient with mild dysphagia in the TDT group after treatment. The
dysphagia severity was signiﬁcantly different between groups after
treatment (ManneWhitney U test, p< 0.001).
The frequency of the aspiration severity in terms of the MASA
test in both groups is demonstrated in Table 6. Therewas no patient
with aspiration in the TDT group after treatment. The aspiration
Fig. 1. Flow diagram of patients.
Table 3
Characteristics of the patients at baseline in Traditional Dysphgia Therapy (TDT) and Usual Care (UC) groups.
TDT
(N¼ 10)
UC
(N¼ 10)
Test
(P-value)
Age (mean± SD) 47.5 (±12.9) 39.9 (±9.7) Independent T-test
(0.15)
Gender (Male/Female) (2/8) (5/5) Chi-square test
(0.35)
Age at onset (mean± SD) 40.7(±12.1) 33.4(±7.9) Independent T-test
(0.13)
Disease Duration (years) (mean± SD) 6.8 (±2.9) 6.1 (±2.7) Independent T-test
(0.76)
EDSSc (mean± SD) 3.6 (±2.1) 3.2 (±2.5) Independent T-test
.(0.7)
MS Type (%)
RRb
PPc
SPd
4 (40%)
4 (40%)
2 (20%)
7(70%)
1(10%)
2 (20%)
Mann-Whitney U test,
(0.4)
a: Expanded Disability Status Scale; b: Relapse-Remitting; c: Primary Progressive; d: Secondary Progressive.
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(ManneWhitney U test, p¼ 0.005).
4.2. Secondary outcome measures
The PAS and PRSS scores were signiﬁcantly improved across thetime in both groups (P< 0.05) (Table 2). The PAS and PRSS scores
were signiﬁcantly different between groups after treatment in
favor of the TDT group (P< 0.001). The large effect sizes were found
for both groups; TDT group: PAS (d¼ 3.18) and PRSS (d¼ 2.26), UC
group: PAS (d¼ 2.75) and PRSS (d¼ 2.06).
Table 4
Mean (SD) of MASA score and Median (Interquartile Range) of PAS and PRRS for Traditional Dysphgia Therapy (TDT) and Usual Care (UC) groups.
TDT UC P-valued
T0 T1 T2 T3 T0 T1 T2 T3
MASAa 148.3
(10.7)
170.5
(6.10)
181.7
(3.47)
183.4
(4.60)
147.9
(15.7)
158.1
(11.82)
163.3
(11.48)
159.3
(13.01)
0.94
PASb 5.5
(4e6)
e 1
(1-1)
e 6
(4.75e6.25)
e 2.5
(2e3)
e 0.18
PRSSc 2
(1e2.25)
e 0 e 3m
(2.75e3)
e 1.5
(1e2)
e 0.10
T0: before treatment; T1: 9th session of treatment; T2: 18th session of treatment; T3: after 6 weeks follow up.
a: Mann Assessment of Swallowing Ability; b: Penetration-Aspiration Scale; c: Pharyngeal Residue Severity Scale; d: between group comparisons at T0.
Fig. 2. Interaction of time and group for MASA scores.
Table 5
Severity of dysphagia in terms of MASA test over the time in the Traditional Dys-
phgia Therapy (TDT) and Usual Care (UC) groups.
TDT UC
T0 T1 T2 T3 T0 T1 T2 T3
No 0 2 9 9 0 0 1 1
2Mild 0 6 1 1 1 4 4
Moderate 8 2 0 0 5 5 5 7
Severe 2 0 0 0 4 1 0 0
T0: before treatment; T1: 9th session of treatment; T2: 18th session of treatment; T3:
after 6 weeks follow up.
Table 6
Severity of aspiration in terms of MASA test over the time in the Traditional Dys-
phgia Therapy (TDT) and Usual Care (UC) groups.
TDT UC
T0 T1 T2 T3 T0 T1 T2 T3
No 0 5 10 10 0 1 4 3
5Mild 4 5 0 0 5 6 5
Moderate 4 0 0 0 1 3 1 2
Severe 2 0 0 0 4 0 0 0
T0: before treatment; T1: 9th session of treatment; T2: 18th session of treatment; T3:
after 6 weeks follow up.
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Dysphagia treatment approaches most frequently involve
rehabilitative strategies (Logemann, 1998). To the best of our
knowledge, this pilot study was the ﬁrst randomized clinical trial to
date investigating the effects of the traditional dysphagia therapy
on the swallowing function in MS patients with dysphagia. The
results showed that theMASA, PAS, and PRRS scores have improved
across the time in both groups. The improvements of the MASA,
PAS, and PRRS scores were signiﬁcantly greater in the TDT group.5.1. Primary outcome measure
This study showed that the MASA score was improved across
the time in both groups, but the improvements of the MASA score
was different between groups. The MASA scores progressively
improved in TDT group and the improvements maintained 6 weeks
after the end of treatment. The MASA score in the UC group was
signiﬁcantly improved only at T1 and signiﬁcantly worsened at T3.
In addition, there was a signiﬁcant interaction between time and
group on the MASA score such that the TDT group showed more
improvements across the time than the UC group. There is not a
study with which to compare the results of the current study. The
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improve the underlying pathophysiology, mainly weakness and
reduced endurance, sensory thresholds, tone, timing, and coordi-
nation, but the UC temporarily eliminates the symptoms of
dysphagia and do not change the swallowing physiology
(Logemann, 1998; Rosenbek and Joes, 2009).
This study demonstrated the large effect sizes of MASA score
after the end of treatment in both the TDTand the UC groups. These
ﬁndings suggest that the both interventions were highly effective in
improving the swallowing function in MS patients with dysphagia.
However, the effect size obtained for MASA score in the TDT group
was remarkably larger than that in the UC group (3.91 VS 1.11)
which indicates that more signiﬁcant improvements have occurred
in the TDT group.
The ﬁndings indicated that there was only one patient with mild
dysphagia and no patient with aspiration in the TDT group after
treatment. But, therewere 9 patients with dysphagia and 6 patients
with aspiration after treatment in the UC group. The signiﬁcant
differences between two groups on the frequency of the dysphagia
severity and the aspiration severity indicated that the TDT is more
effective than the UC.
5.2. Secondary outcome measures
The results of our study revealed that the PAS and PRRS scores
were decreased after 6 weeks treatment in both groups, but the
decrease of the PAS and PRRS scores in the TDT group were
signiﬁcantly greater than the UC group. These ﬁndings indicate that
although oral feeding becomes safer after treatment in both groups,
but the TDT techniques have been more effective in reducing
penetration, aspiration and pharyngeal residue than the UC
techniques.
Generally, both therapeutic strategies resulted in improved
swallowing function in MS patients with dysphagia, but the
improvement was signiﬁcantly greater in the TDT group. The
ﬁndings of the present study are in accordance with the previous
studies (Prosiegel et al., 2004; Logemann, 2006a,b; Restivo et al.,
2006; Giusti and Giambuzzi, 2008). The improvements in the TDT
group may be assumed that achieved through the skilled move-
ments needed for safe, efﬁcient, and satisfying swallowing as well
as alerting the pathophysiology underlying the abnormal swal-
lowing. The UC techniques may simply accommodate the impaired
movements by practices such as diet modiﬁcation, postural
changes, and some alteration in how or what the patients can eat
and drink (Logemann, 1991, 1998; Carnaby-Mann et al., 2006).
The main limitation of this study could be that the sample size
was very small. Future studies with larger sample sizes are there-
fore needed for generalization of the results.
6. Conclusion
This study demonstrated that the traditional dysphagia therapy
was effective in improving swallowing function inMS patients with
dysphagia. The future clinical trials are needed to compare the
traditional dysphagia therapy with other dysphagia treatment
techniques.
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